

Thomas Tran, MBA
+33 646 785 687

June 2026
www.aceso-therapeutics.com



ACT-101

A n o v e l A S O T h e r a p y f o r c y s t i c f i b r o s i s

*" T o r e n e w b r e a t h
a n d r e s t o r e l i f e
f o r m o r e p a t i e n t s "*


Executive Summary

- 01** First-in-class patented antisense oligonucleotide therapy for cystic fibrosis.
- 02** €1.5M invested — lead candidate already 25% toward IND submission by end-2027.
- 03** A €2M seed round in July 2026 to fund regulatory preclinical.
- 04** CFTR modulator market €30B – 200k patients by 2035
Phase 2 efficacy by 2031 to unlock potential partnership.



Cystic fibrosis (CF) is a **rare genetic disease** caused by CFTR mutations, with F508del being the most common.

Cystic Fibrosis



120 000

Patients diagnosed worldwide

80%

Eligible for CFTR modulators

20%

Unmet needs in 20% of patients


In 2023 50% of patients were treated, within a market of ~€9B

ACT-101

Our technology

ASO therapy designed to enhance CFTR activity by increasing CFTR mRNA expression

Target Site Blocker (TSB) ASO



Why Us?

An opportunity to invest in July 2026 in our program ACT-101.

Unmet medical need – CF rare disease not addressed properly

Technology – New ASO therapy for CF – Scalable to additional therapeutic indications.

Value – Clear roadmap to secure value creation (→ 2031)



Leadership team



MBA
Thomas Tran
CEO



PHD
Magali Taulan-Cadars
CSO, expert genetic - ASO



PHD
Prisca Boisguerin
CTO, expert biochemistry
Peptide - CMC



PHD
Sébastien Cagnol
Preclinical leader ACT-101
expert small molecule

Thank You

Join us
"To renew breath and restore life for more patients"